BlackRock, Inc. Increases Stake in Lexeo Therapeutics, Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G/A, disclosing an increase in its ownership of Lexeo Therapeutics, Inc. common stock. As of September 30, 2025, BlackRock owns 2,168,444 shares, representing 4.0% of the total outstanding shares. This marks a significant increase from its previous holdings, with a value change of $13,425,277.52 and a shares change of 340,480. The filing indicates that BlackRock acquired these shares in the ordinary course of business and not for the purpose of influencing the control of Lexeo Therapeutics. The filing also includes certifications and exhibits, such as a Power of Attorney and details on subsidiary identification.